SI3452448T1 - Modulatorji integrirane stresne poti - Google Patents

Modulatorji integrirane stresne poti

Info

Publication number
SI3452448T1
SI3452448T1 SI201731474T SI201731474T SI3452448T1 SI 3452448 T1 SI3452448 T1 SI 3452448T1 SI 201731474 T SI201731474 T SI 201731474T SI 201731474 T SI201731474 T SI 201731474T SI 3452448 T1 SI3452448 T1 SI 3452448T1
Authority
SI
Slovenia
Prior art keywords
modulators
integrated stress
stress pathway
pathway
integrated
Prior art date
Application number
SI201731474T
Other languages
English (en)
Slovenian (sl)
Inventor
Carmela Sidrauski
Marina Pliushchev
Jennifer M. Frost
Lawrence A. Black
Xiangdong Xu
Ramzi Farath Sweis
Lei Shi
Qingwei Zhang
Yunsong Tong
Charles W. Hutchins
Seungwon Chung
Michael J. Dart
Original Assignee
Calico Life Sciences Llc
Abbvie Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calico Life Sciences Llc, Abbvie Inc. filed Critical Calico Life Sciences Llc
Publication of SI3452448T1 publication Critical patent/SI3452448T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/18—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides
    • C07C235/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
    • C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/23—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms
    • C07C311/24—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C07D213/66—One oxygen atom attached in position 3 or 5 having in position 3 an oxygen atom and in each of the positions 4 and 5 a carbon atom bound to an oxygen, sulphur, or nitrogen atom, e.g. pyridoxal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C07D237/16—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/18—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/64—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/08—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00Ā -Ā C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00Ā -Ā C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/38—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing five carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/40—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing six carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/44—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing eight carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/90—Ring systems containing bridged rings containing more than four rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
SI201731474T 2016-05-05 2017-05-05 Modulatorji integrirane stresne poti SI3452448T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662332278P 2016-05-05 2016-05-05
PCT/US2017/031360 WO2017193034A1 (en) 2016-05-05 2017-05-05 Modulators of the integrated stress pathway
EP17723899.5A EP3452448B1 (en) 2016-05-05 2017-05-05 Modulators of the integrated stress pathway

Publications (1)

Publication Number Publication Date
SI3452448T1 true SI3452448T1 (sl) 2024-04-30

Family

ID=58709639

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201731474T SI3452448T1 (sl) 2016-05-05 2017-05-05 Modulatorji integrirane stresne poti

Country Status (38)

Country Link
US (3) US20190144440A1 (https=)
EP (2) EP3452448B1 (https=)
JP (4) JP6997766B2 (https=)
KR (3) KR20250042188A (https=)
CN (2) CN109641844B (https=)
AR (1) AR110599A1 (https=)
AU (3) AU2017260367B2 (https=)
BR (1) BR112018072663A2 (https=)
CA (1) CA3023162A1 (https=)
CL (1) CL2018003142A1 (https=)
CO (1) CO2018012946A2 (https=)
CR (2) CR20210372A (https=)
DK (1) DK3452448T3 (https=)
DO (1) DOP2018000242A (https=)
EC (1) ECSP18089579A (https=)
ES (1) ES2973442T3 (https=)
FI (1) FI3452448T3 (https=)
HR (1) HRP20240218T1 (https=)
HU (1) HUE065713T2 (https=)
IL (3) IL286693B2 (https=)
LT (1) LT3452448T (https=)
MA (1) MA44861B1 (https=)
MD (1) MD3452448T2 (https=)
MX (2) MX383652B (https=)
MY (1) MY200943A (https=)
PE (2) PE20231935A1 (https=)
PH (1) PH12018502329B1 (https=)
PL (1) PL3452448T3 (https=)
PT (1) PT3452448T (https=)
RS (1) RS65214B1 (https=)
RU (2) RU2022106770A (https=)
SG (1) SG11201809695TA (https=)
SI (1) SI3452448T1 (https=)
SM (1) SMT202400098T1 (https=)
TW (2) TWI763668B (https=)
UA (1) UA125513C2 (https=)
UY (2) UY40873A (https=)
WO (1) WO2017193034A1 (https=)

Families Citing this family (31)

* Cited by examiner, ā€  Cited by third party
Publication number Priority date Publication date Assignee Title
CN110730777A (zh) * 2017-06-07 2020-01-24 č‘›å…°ē“ å²åƆę–Æå…‹čŽ±ēŸ„čƆäŗ§ęƒå‘å±•ęœ‰é™å…¬åø 作äøŗatf4通č·ÆęŠ‘åˆ¶å‰‚ēš„化学化合ē‰©
US20210145771A1 (en) * 2017-07-03 2021-05-20 Glaxosmithkline Intellectual Property Development Limited N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1] pentan-1-yl)-2-cyclobutane-1- carboxamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases
CN118239937A (zh) * 2017-08-09 2024-06-25 ꈓēŗ³ē«‹åˆ¶čÆ公åø 化合ē‰©ć€ē»„合ē‰©åŠę–¹ę³•
DK3676297T3 (da) 2017-09-01 2023-08-14 Denali Therapeutics Inc Forbindelser, sammensƦtninger og fremgangsmƄder
UY37956A (es) * 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vƭa de estrƩs integrada
UY37958A (es) * 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vƭa de estrƩs integrada
US11939320B2 (en) 2017-11-02 2024-03-26 Abbvie Inc. Modulators of the integrated stress pathway
WO2019118785A2 (en) 2017-12-13 2019-06-20 Praxis Biotech LLC Inhibitors of integrated stress response pathway
WO2019183589A1 (en) * 2018-03-23 2019-09-26 Denali Therapeutics Inc. Modulators of eukaryotic initiation factor 2
WO2019236710A1 (en) 2018-06-05 2019-12-12 Praxis Biotech LLC Inhibitors of integrated stress response pathway
JP2021529814A (ja) * 2018-07-09 2021-11-04 ć‚°ćƒ©ć‚Æć‚½ć‚¹ćƒŸć‚¹ć‚Æćƒ©ć‚¤ćƒ³ć€ć‚¤ćƒ³ćƒ†ćƒ¬ć‚Æćƒćƒ„ć‚¢ćƒ«ć€ćƒ—ćƒ­ćƒ‘ćƒ†ć‚£ćƒ¼ć€ćƒ‡ć‚£ćƒ™ćƒ­ćƒƒćƒ—ćƒ”ćƒ³ćƒˆć€ćƒŖ惟惆惃惉ļ¼§ļ½Œļ½ļ½˜ļ½ļ½“ļ½ļ½‰ļ½”ļ½ˆļ½‹ļ½Œļ½‰ļ½Žļ½… ļ¼©ļ½Žļ½”ļ½…ļ½Œļ½Œļ½…ļ½ƒļ½”ļ½•ļ½ļ½Œ ļ¼°ļ½’ļ½ļ½ļ½…ļ½’ļ½”ļ½™ ļ¼¤ļ½…ļ½–ļ½…ļ½Œļ½ļ½ļ½ļ½…ļ½Žļ½” ļ¼¬ļ½‰ļ½ļ½‰ļ½”ļ½…ļ½„ 化学化合ē‰©
TWI877863B (zh) * 2018-10-11 2025-03-21 ē¾Žå•†å˜‰ä¾†å…‹ē”Ÿå‘½ē§‘å­øęœ‰é™č²¬ä»»å…¬åø ę•“åˆę‡‰ęæ€č·Æå¾‘ä¹‹å‰č—„čŖæēƀ劑
MA54953A (fr) * 2019-02-13 2021-12-22 Denali Therapeutics Inc ComposƩs, compositions et procƩdƩs
US12091392B2 (en) 2019-02-13 2024-09-17 Denali Therapeutics Inc. Compounds, compositions and methods
US20200270232A1 (en) * 2019-02-25 2020-08-27 Praxis Biotech LLC Inhibitors of integrated stress response pathway
CA3137213A1 (en) 2019-04-23 2020-10-29 Evotec International Gmbh Modulators of the integrated stress response pathway
MX2021012904A (es) 2019-04-23 2022-01-18 Evotec Int Gmbh Moduladores de la via de respuesta al estres integrada.
AR118836A1 (es) * 2019-04-30 2021-11-03 Calico Life Sciences Llc Moduladores de la vĆ­a de tensiĆ³n integrada
MX2021013197A (es) * 2019-04-30 2022-02-24 Calico Life Sciences Llc Cicloalquilos sustituidos como moduladores de la vƭa integrada del estrƩs.
JP2022536663A (ja) 2019-06-12 2022-08-18 ćƒ—ćƒ©ć‚Æć‚·ć‚¹ 惐悤ć‚Ŗ惆惃ć‚Æ ć‚Ø惫ć‚Øćƒ«ć‚·ćƒ¼ ēµ±åˆēš„ć‚¹ćƒˆćƒ¬ć‚¹åæœē­”ēµŒč·Æć®ćƒ¢ć‚øćƒ„ćƒ¬ćƒ¼ć‚æćƒ¼
BR112022010924A2 (pt) * 2019-12-06 2022-09-06 Vertex Pharma Tetra-hidrofuranos substituĆ­dos como moduladores de canais de sĆ³dio
AU2021213289A1 (en) 2020-01-28 2022-07-07 Evotec International Gmbh Modulators of the integrated stress response pathway
MX2022011143A (es) 2020-03-11 2022-10-13 Evotec Int Gmbh Moduladores de la via de respuesta integrada al estres.
JP2023533016A (ja) 2020-07-11 2023-08-01 ćƒ•ć‚”ć‚¤ć‚¶ćƒ¼ćƒ»ć‚¤ćƒ³ć‚Æ ęŠ—ć‚¦ć‚¤ćƒ«ć‚¹ę€§ćƒ˜ćƒ†ćƒ­ć‚¢ćƒŖćƒ¼ćƒ«ć‚±ćƒˆćƒ³čŖ˜å°Žä½“
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
US20230391763A1 (en) 2020-10-22 2023-12-07 Evotec International Gmbh Modulators of the integrated stress response pathway
MX2023004623A (es) 2020-10-22 2023-05-12 Evotec Int Gmbh Moduladores de la via integrada de respuesta al estres.
JP2023546224A (ja) 2020-10-22 2023-11-01 ć‚Øćƒ“ć‚©ćƒ†ćƒƒć‚Æćƒ»ć‚¤ćƒ³ć‚æćƒ¼ćƒŠć‚·ćƒ§ćƒŠćƒ«ćƒ»ć‚²ć‚¼ćƒ«ć‚·ćƒ£ćƒ•ćƒˆćƒ»ćƒŸćƒƒćƒˆćƒ»ćƒ™ć‚·ćƒ„ćƒ¬ćƒ³ć‚Æćƒ†ćƒ«ćƒ»ćƒćƒ•ćƒ„ćƒ³ć‚° ēµ±åˆć‚¹ćƒˆćƒ¬ć‚¹åæœē­”ēµŒč·Æć®ćƒ¢ć‚øćƒ„ćƒ¬ćƒ¼ć‚æćƒ¼
CN116685319A (zh) * 2020-12-10 2023-09-01 é˜æå¾·ę ¼ē½—ē”Ÿē‰©åˆ¶čÆęŽ§č‚”ęœ‰é™å…¬åø ē”ØäŗŽę²»ē–—ēš®č‚¤č½¬ē§»ę€§ē™Œēš„ę–¹ę³•
KR20250122004A (ko) * 2024-02-05 2025-08-13 ģž¬ė‹Øė²•ģø ėŒ€źµ¬ź²½ė¶ģ²Øė‹Øģ˜ė£Œģ‚°ģ—…ģ§„ķ„ģž¬ė‹Ø ģ‹ ź·œķ•œ eIF2B ģž‘ģš©ģ œ ė° ģ“ė„¼ ķ¬ķ•Øķ•˜ėŠ” ėŒ€ģ‚¬ģ§ˆķ™˜ ģ˜ˆė°© ė˜ėŠ” ģ¹˜ė£Œģš© ģ”°ģ„±ė¬¼
WO2025255324A1 (en) * 2024-06-06 2025-12-11 Lapis Therapeutics, Inc. Inhibitors of lipoprotein(a) assembly

Family Cites Families (18)

* Cited by examiner, ā€  Cited by third party
Publication number Priority date Publication date Assignee Title
US5212A (en) 1847-07-31 Richard m
US162A (en) 1837-04-17 Island
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
JP2594486B2 (ja) 1991-01-15 1997-03-26 ć‚¢ćƒ«ć‚³ćƒ³ ćƒ©ćƒœćƒ©ćƒˆćƒŖćƒ¼ć‚ŗ ć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ć‚¤ćƒ†ćƒƒćƒ‰ å±€ę‰€ēš„ēœ¼č–¬ēµ„ęˆē‰©
GB0400196D0 (en) * 2004-01-07 2004-02-11 Astrazeneca Ab Therapeutic agents
EP1706384A1 (en) * 2004-01-07 2006-10-04 AstraZeneca AB Therapeutic agents i
US7842707B2 (en) * 2004-07-23 2010-11-30 Nuada, Llc Peptidase inhibitors
GB0516314D0 (en) * 2005-08-08 2005-09-14 Argenta Discovery Ltd Compound
JP2009504624A (ja) * 2005-08-08 2009-02-05 ć‚¢ćƒ¼ć‚øć‚§ćƒ³ć‚æ ćƒ‡ć‚£ć‚¹ć‚«ćƒćƒŖćƒ¼ ćƒŖ惟惆惃惉 ćƒ“ć‚·ć‚Æ惭ļ¼»ļ¼’ļ¼Žļ¼’ļ¼Žļ¼‘ļ¼½ćƒ˜ćƒ—ć‚æāˆ’ļ¼—āˆ’ć‚¤ćƒ«ć‚¢ćƒŸćƒ³čŖ˜å°Žä½“ćŠć‚ˆć³ćć®ä½æē”Ø
JP2009504628A (ja) 2005-08-10 2009-02-05 ćƒ•ć‚”ć‚¤ć‚¶ćƒ¼ćƒ»ćƒŖ惟惆惃惉 ć‚Ŗć‚­ć‚·ćƒˆć‚·ćƒ³ę‹®ęŠ—č–¬ćØ恗恦恮ē½®ę›ćƒˆćƒŖć‚¢ć‚¾ćƒ¼ćƒ«čŖ˜å°Žä½“
EP2205241B1 (en) * 2007-09-25 2014-05-21 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
TW201134820A (en) * 2010-03-17 2011-10-16 Axikin Pharmaceuticals Inc Arylsulfonamide CCR3 antagonists
EP2604601B1 (en) * 2010-08-10 2016-02-24 Astellas Pharma Inc. Hetero ring compound
AR084457A1 (es) * 2010-12-22 2013-05-15 Lundbeck & Co As H Derivados de biciclo[3,2,1]octilamida
JP6806562B2 (ja) * 2013-03-15 2021-01-06 悶 ćƒŖćƒ¼ć‚øć‚§ćƒ³ćƒ„ ć‚Ŗ惖 悶 ćƒ¦ćƒ‹ćƒćƒ¼ć‚·ćƒ†ć‚£ ć‚Ŗ惖 ć‚«ćƒŖćƒ•ć‚©ćƒ«ćƒ‹ć‚¢ ļ½…ļ¼©ļ¼¦ļ¼’Ī±ēµŒč·Æ恮čŖæēƀ因子
US20160318856A1 (en) * 2013-09-11 2016-11-03 The Brigham And Women's Hospital, Inc. Substituted Urea eIF2alpha Kinase Activators
CN110229142A (zh) * 2014-04-04 2019-09-13 åøŒę“›ę–Æ医čÆå“č‚”ä»½ęœ‰é™å…¬åø ē»†čƒžå‘Øꜟ蛋ē™½ä¾čµ–ꀧęæ€é…¶7(cdk7)ēš„ęŠ‘åˆ¶å‰‚

Also Published As

Publication number Publication date
BR112018072663A2 (pt) 2019-02-19
AU2017260367A1 (en) 2018-11-22
IL262722A (en) 2018-12-31
ECSP18089579A (es) 2019-02-28
CO2018012946A2 (es) 2019-08-20
IL262722B (en) 2021-10-31
JP2019515043A (ja) 2019-06-06
RU2022106770A (ru) 2022-04-05
JP6997766B2 (ja) 2022-01-20
EP4356971A3 (en) 2024-07-24
RU2018142740A (ru) 2020-06-05
MX2021007146A (es) 2022-11-29
CN115947681A (zh) 2023-04-11
HUE065713T2 (hu) 2024-06-28
LT3452448T (lt) 2024-03-12
PT3452448T (pt) 2024-03-19
JP7755632B2 (ja) 2025-10-16
MX2018013495A (es) 2019-07-04
UY40873A (es) 2024-09-13
MX383652B (es) 2025-03-14
KR20190031203A (ko) 2019-03-25
JP2022046578A (ja) 2022-03-23
TW201808887A (zh) 2018-03-16
WO2017193034A1 (en) 2017-11-09
NZ747842A (en) 2025-05-30
EP4356971A2 (en) 2024-04-24
CN109641844A (zh) 2019-04-16
ES2973442T3 (es) 2024-06-20
RS65214B1 (sr) 2024-03-29
CL2018003142A1 (es) 2019-05-24
SG11201809695TA (en) 2018-11-29
TW202304851A (zh) 2023-02-01
MA44861A (fr) 2019-03-13
AU2022200946A1 (en) 2022-03-03
SMT202400098T1 (it) 2024-05-14
KR20250042188A (ko) 2025-03-26
CR20180574A (es) 2019-05-15
MY200943A (en) 2024-01-24
HRP20240218T1 (hr) 2024-04-26
AU2017260367B2 (en) 2021-12-02
US20220363678A1 (en) 2022-11-17
PE20231935A1 (es) 2023-12-05
CN109641844B (zh) 2022-11-01
PL3452448T3 (pl) 2024-07-08
TWI844006B (zh) 2024-06-01
IL323840A (en) 2025-12-01
TWI763668B (zh) 2022-05-11
IL286693A (en) 2021-10-31
PH12018502329A1 (en) 2019-03-25
KR102512049B1 (ko) 2023-03-21
DK3452448T3 (da) 2024-02-12
UY37228A (es) 2017-11-30
EP3452448A1 (en) 2019-03-13
JP2024023324A (ja) 2024-02-21
IL286693B2 (en) 2026-03-01
PE20190348A1 (es) 2019-03-07
MD3452448T2 (ro) 2024-04-30
US20190144440A1 (en) 2019-05-16
JP2026009986A (ja) 2026-01-21
DOP2018000242A (es) 2019-04-15
CA3023162A1 (en) 2017-11-09
RU2018142740A3 (https=) 2020-08-24
PH12018502329B1 (en) 2023-08-11
FI3452448T3 (fi) 2024-03-19
US20250122188A1 (en) 2025-04-17
TW202506629A (zh) 2025-02-16
JP7389786B2 (ja) 2023-11-30
AR110599A1 (es) 2019-04-17
IL286693B1 (en) 2025-11-01
CR20210372A (es) 2022-06-07
CN115947681B (zh) 2025-10-14
RU2769327C2 (ru) 2022-03-30
UA125513C2 (uk) 2022-04-13
KR20230042146A (ko) 2023-03-27
AU2024227527A1 (en) 2024-11-14
KR102781404B1 (ko) 2025-03-18
NZ787908A (en) 2025-05-30
MA44861B1 (fr) 2024-02-29
EP3452448B1 (en) 2023-12-20
AU2022200946B2 (en) 2024-07-25

Similar Documents

Publication Publication Date Title
IL274369A (en) Combined pressure pathway modulators
IL274368A (en) Combined pressure pathway modulators
IL274405A (en) Combined pressure pathway modulators
IL274367A (en) Combined pressure pathway modulators
IL274406A (en) Combined pressure pathway modulators
PT3452454T (pt) Moduladores da via integrada ao stresse
SMT202400098T1 (it) Modulatori della via dello stress integrata
IL282153B1 (en) Pro-drugs that modulate pathways of combined stress
IL262303A (en) Modulators of nlrp3
IL259421B (en) ror - gamma modulators
IL271935A (en) NLRP3 modulators
PL3303293T3 (pl) Modulatory ROR-gamma
PL3303291T3 (pl) Modulatory ROR-gamma
PL3303290T3 (pl) Modulatory ROR-gamma
GB201716468D0 (en) Modulators
IL266265A (en) Functional chocolate
IL266261A (en) ror-gamma modulators
PL3319942T3 (pl) MODULATORY ROR-GAMMA (RORĪ³)
GB2563095B (en) Modulators
GB2549084B (en) Fixing
HK40037522A (en) Modulators of the integrated stress pathway
HK40037528A (en) Modulators of the integrated stress pathway
HK40037523A (en) Modulators of the integrated stress pathway
HK40037177A (en) Modulators of the integrated stress pathway
HK40012050A (en) Modulators of the integrated stress pathway